Literature DB >> 33413475

Modulation of BRD4 in HIV epigenetic regulation: implications for finding an HIV cure.

Edrous Alamer1,2,3, Chaojie Zhong1, Renee Hajnik1, Lynn Soong1,4, Haitao Hu5,6.   

Abstract

Following reverse transcription, HIV viral DNA is integrated into host cell genomes and establishes a stable latent infection, which has posed a major obstacle for obtaining a cure for HIV. HIV proviral transcription is regulated in cellular reservoirs by complex host epigenetic and transcriptional machineries. The Bromodomain (BD) and Extra-Terminal Domain (ET) protein, BRD4, is an important epigenetic reader that interacts with acetyl-histones and a variety of chromatin and transcriptional regulators to control gene expression, including HIV. Modulation of BRD4 by a pan BET inhibitor (JQ1) has been shown to activate HIV transcription. Recent studies by my group and others indicate that the function of BRD4 is versatile and its effects on HIV transcription may depend on the partner proteins or pathways engaged by BRD4. Our studies have reported a novel class of small-molecule modulators that are distinct from JQ1 but induce HIV transcriptional suppression through BRD4. Herein, we reviewed recent research on the modulation of BRD4 in HIV epigenetic regulation and discussed their potential implications for finding an HIV cure.

Entities:  

Keywords:  BRD4; Epigenetic regulation; HIV; Latency

Year:  2021        PMID: 33413475      PMCID: PMC7792063          DOI: 10.1186/s12977-020-00547-9

Source DB:  PubMed          Journal:  Retrovirology        ISSN: 1742-4690            Impact factor:   4.602


  75 in total

1.  Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA.

Authors:  Bo Huang; Xiao-Dong Yang; Ming-Ming Zhou; Keiko Ozato; Lin-Feng Chen
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

2.  HIV reservoirs as obstacles and opportunities for an HIV cure.

Authors:  Tae-Wook Chun; Susan Moir; Anthony S Fauci
Journal:  Nat Immunol       Date:  2015-06       Impact factor: 25.606

3.  Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.

Authors:  Gregory M Laird; C Korin Bullen; Daniel I S Rosenbloom; Alyssa R Martin; Alison L Hill; Christine M Durand; Janet D Siliciano; Robert F Siliciano
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

4.  The accuracy of reverse transcriptase from HIV-1.

Authors:  J D Roberts; K Bebenek; T A Kunkel
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

5.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

Authors:  B Ramratnam; J E Mittler; L Zhang; D Boden; A Hurley; F Fang; C A Macken; A S Perelson; M Markowitz; D D Ho
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

6.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

7.  Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy.

Authors:  Angelos E Hatzakis; Giota Touloumi; Nikos Pantazis; Cleo G Anastassopoulou; Olga Katsarou; Anastasia Karafoulidou; James J Goedert; Leondios G Kostrikis
Journal:  AIDS       Date:  2004-11-19       Impact factor: 4.177

8.  Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication.

Authors:  Seongwoo Hwang; Natarajan Tamilarasu; Karen Kibler; Hong Cao; Akbar Ali; Yueh-Hsin Ping; Kuan-Teh Jeang; Tariq M Rana
Journal:  J Biol Chem       Date:  2003-07-11       Impact factor: 5.157

9.  Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription.

Authors:  Dwayne A Bisgrove; Tokameh Mahmoudi; Peter Henklein; Eric Verdin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-09       Impact factor: 11.205

10.  Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat.

Authors:  Chuan Li; Guillaume Mousseau; Susana T Valente
Journal:  Epigenetics Chromatin       Date:  2019-04-16       Impact factor: 4.954

View more
  5 in total

Review 1.  Bromodomains in Human-Immunodeficiency Virus-Associated Neurocognitive Disorders: A Model of Ferroptosis-Induced Neurodegeneration.

Authors:  Adonis Sfera; Karina G Thomas; Christina V Andronescu; Nyla Jafri; Dan O Sfera; Sarvin Sasannia; Carlos M Zapata-Martín Del Campo; Jose C Maldonado
Journal:  Front Neurosci       Date:  2022-05-12       Impact factor: 5.152

Review 2.  Role of Histone Post-Translational Modifications in Inflammatory Diseases.

Authors:  Yingying Lin; Ting Qiu; Guifeng Wei; Yueyue Que; Wenxin Wang; Yichao Kong; Tian Xie; Xiabin Chen
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

Review 3.  Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?

Authors:  Thanarat Salahong; Christian Schwartz; Rungroch Sungthong
Journal:  Viruses       Date:  2021-05-29       Impact factor: 5.048

Review 4.  Induction of Autophagy to Achieve a Human Immunodeficiency Virus Type 1 Cure.

Authors:  Grant R Campbell; Stephen A Spector
Journal:  Cells       Date:  2021-07-16       Impact factor: 7.666

5.  Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment.

Authors:  Xu-Sheng Huang; Ren-Rong Tian; Meng-Di Ma; Rong-Hua Luo; Liu-Meng Yang; Guang-Hui Peng; Mi Zhang; Xing-Qi Dong; Yong-Tang Zheng
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.